Table 5.

Incidence of major bleeding according to antithrombotic therapy

	N (%)	Total, N = 597 % pts/year (95% CI)	Antiplatelet agents, n = 486 % pts/year (95% CI)	Anticoagulant agents, n = 65 % pts/year (95% CI)	p-valuea
Major bleeding	25 (4)	0.90 (0.61–1.35)	0.94 (0.61–1.44)	0.79 (0.20–3.16)	0.980
CNS bleeding	8 (1.3)	0.30 (0.15–0.59)	0.35 (0.18–0.70)	0 (0)	0.426
GI bleeding	8 (1.3)	0.26 (0.12–0.55)	0.26 (0.12–0.59)	0.40 (0.06–2.81)	0.674
Muscle hematoma	5 (0.8)	0.19 (0.08–0.45)	0.18 (0.07–0.47)	0.39 (0.05–2.77)	0.497
Epistaxis	4 (0.6)	0.15 (0.06–0.40)	0.13 (0.04–0.41)	0 (0)	0.726

CNS cerebral nervous system, GI gastrointestinal

^aTests for differences in incidence rate between antiplatelet agents and anticoagulant agents groups